Israeli oncology company Alpha Tau Medical Ltd. (DRTS) drew strong attention after the stock surged to a new 52-week high of $5.07 on December 10. It closed at $5.06, marking a 19.62% gain for the day, and extended its rise to $5.20 in after-hours trading. The strong price action comes at a time when the company is advancing several clinical programs, expanding its manufacturing capabilities, and preparing for multiple regulatory and clinical milestones across 2025 and 2026. These developments have placed the stock firmly on the radar as Alpha Tau continues to progress its Alpha DaRT radiation therapy platform.
What the Company Does
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.